Nwam LLC Boosts Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Nwam LLC grew its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 9.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,000,351 shares of the biotechnology company's stock after acquiring an additional 87,300 shares during the quarter. Anavex Life Sciences accounts for 0.7% of Nwam LLC's portfolio, making the stock its 19th largest holding. Nwam LLC owned approximately 1.17% of Anavex Life Sciences worth $8,583,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in Anavex Life Sciences by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company's stock valued at $7,273,000 after buying an additional 11,239 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Anavex Life Sciences during the 4th quarter worth $210,000. Raymond James Financial Inc. bought a new stake in shares of Anavex Life Sciences during the 4th quarter worth $167,000. Commonwealth Equity Services LLC raised its position in shares of Anavex Life Sciences by 7.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 102,662 shares of the biotechnology company's stock worth $1,103,000 after acquiring an additional 7,285 shares during the last quarter. Finally, Intech Investment Management LLC grew its holdings in Anavex Life Sciences by 79.9% in the fourth quarter. Intech Investment Management LLC now owns 42,383 shares of the biotechnology company's stock worth $455,000 after purchasing an additional 18,827 shares during the period. 31.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on AVXL. HC Wainwright reissued a "buy" rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th.

Anavex Life Sciences Trading Up 0.7%

Shares of NASDAQ AVXL traded up $0.08 during trading hours on Monday, reaching $11.06. The stock had a trading volume of 200,500 shares, compared to its average volume of 1,185,087. Anavex Life Sciences Corp. has a fifty-two week low of $4.93 and a fifty-two week high of $14.44. The firm has a market cap of $944.75 million, a price-to-earnings ratio of -20.11 and a beta of 0.72. The firm has a 50-day moving average of $8.98 and a 200-day moving average of $9.12.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. During the same quarter last year, the company earned ($0.13) EPS. On average, equities analysts predict that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.